Bank of America
MDGL icon

Bank of America’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bank of America’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$2.31M – 8016
2023
Q4 		$2.31M Buy
+10,000
New +$1.75M ﹤0.01% 4259
2023
Q3 		– Sell
-36,100
Closed -$8.34M – 7875
2023
Q2 		$8.34M Buy
+36,100
New +$9.78M ﹤0.01% 2888
2019
Q1 		– Sell
-5,000
Closed -$564K – 7293
2018
Q4 		$564K Hold
5,000
– – ﹤0.01% 4853
2018
Q3 		$1.07M Buy
+5,000
New +$1.25M ﹤0.01% 4437

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America's MDGL Position: Q1 2026 in Review

Bank of America reduced its Madrigal Pharmaceuticals (MDGL) stake by 54% in Q1 2026, selling an estimated $108M and leaving 189,527 shares worth $99.2M. The position accounts for 0.01% of the portfolio, ranked #1120.

Bank of America first reported a position in MDGL in Q2 2013 and has held it in 51 quarters since. The position peaked at $242M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Bank of America held 189,527 shares of Madrigal Pharmaceuticals worth $99.2M as of Q1 2026.
  • Bank of America sold 226,498 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $108M.
  • Madrigal Pharmaceuticals made up 0.01% of Bank of America's portfolio in Q1 2026, its #1120 holding.
  • Bank of America first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • Bank of America's Madrigal Pharmaceuticals position peaked at $242M in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.